Drugs / ITI-3000
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05422781 | Jun 2022 → Jun 2023 | cutaneous neuroendocrine carcinoma | Immunomic Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ITI-3000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05422781 ↗ |
| Known as | LTS220A-UNITE | “Vaccination with LTS220A-UNITE™ DNA vaccine (ITI-3000) induced antigen-specific CD4 T cell responses and a strong humoral response that were sufficient to delay tumor growth of...” PMID 37711623 ↗ Aug 2023 |
| Modality | Vaccine | “ITI-3000 is a DNA vaccine” NCT05422781 ↗ |